Published in final edited form as:

Org Lett. 2013 November 15; 15(22): . doi:10.1021/ol4028144.

Chemoenzymatic Synthesis of the Human CD52 and CD24 Antigen Analogs

Zhimeng Wu^a, Xueqing Guo^a, Guofeng Gu^b, and Zhongwu Guo^{a,b}

Zhongwu Guo: zwguo@sdu.edu.cn

^aDepartment of Chemistry, Wayne State University, Detroit, Michigan 48202, USA

^bNational Glycoengineering Research Center, Shandong University, Jinan 250100, China

Abstract

sortase A, CD52 polypeptide-LPKTGGS-OH or
Tris buffer, CD24 polypeptide-LPKTGGS-OH

Analogs of CD52 antigen: R = H or C₁₈H₃₇; R' = AcNH-GQNDTSQTSSPSLPKT-

Analogs of CD24 antigen:

R = H or C₁₈H₃₇; R' = NH₂-SETTTGTSSNSQSSTNSGSLAPNPTNATKALPKT-

Analogs of the human CD52 and CD24 antigens carrying the common core structure of glycosylphosphatidylinositol (GPI) anchors and the intact polypeptide sequences of CD52 and CD24 were chemoenzymatically synthesized. CD52 and CD24 proteins were obtained by solid-phase peptide synthesis and then coupled to chemically synthesized GPI anchors under the influence of a bacterial enzyme, sortase A, to afford the target molecules in good yields.

The human CD52 and CD24 antigens are representative examples of glycosylphosphatidylinositol (GPI)-anchored proteins. These antigens play a vital role in many important biological processes, such as human immune recognition,¹ reproduction,²⁻⁴ and tumor metastasis.⁵⁻⁹ Moreover, they are also excellent models for the study of surface protein GPI anchorage to the extracellular membrane, a common and important phenomenon in eukaryotic species.¹⁰⁻¹³ To gain insight into the biology of CD52 and CD24 antigens and to study protein GPI anchorage and related biological problems, it is necessary to have access to these molecules and their analogs or derivatives in sufficient quantity and purity, which is difficult to achieve through isolation and purification of natural products.

Several general synthetic strategies have been explored to address the challenge in accessing GPI-linked proteins. For instance, our group reported a convergent synthesis of GPI-linked peptides and glycopeptides via regioselective coupling of extensively protected synthetic GPI anchors to peptides/glycopeptides, which was followed by global deprotection.^{14,15} The Bertozzi group¹⁶ and the Seeberger group¹⁷ described the synthesis of GPI-linked proteins

Correspondence to: Zhongwu Guo, zwguo@sdu.edu.cn; zwguo@chem.wayne.edu.

Supporting Information Available. Experimental procedures, ¹H, ¹³C and ³¹P NMR spectra of intermediates involved in GPI synthesis, and mass spectra of the key intermediates and the final products were available free of charge from the website at <http://pubs.acs.org>.

via native chemical ligation (NCL) of Cys-containing GPI analogs and proteins, such as green fluorescent proteins and prion proteins. More recently, our group developed a novel synthetic strategy^{18–20} that utilized sortase A (SrtA), a bacterial enzyme derived from *Staphylococcus aureus*,²¹ to catalyze regioselective coupling of GPIs and peptides or glycopeptides, which may be widely applicable.

In this report, the SrtA-based strategy was used for the synthesis of analogs of the CD52 and CD24 antigens, as outlined in Scheme 1. For this purpose, CD52 and CD24 proteins were designed to have the sorting signal LPXTG (X can be any amino acid) at the peptide C-terminus. SrtA can recognize the signal, react with it to break the peptide bond between T and G and form a reactive complex,²² and finally link the carboxyl group of T to the amino group of G attached to the GPI anchor. GPI anchors utilized in this research were **1** and **2** (Figure 1) containing the intact GPI common core structure without and with a lipid chain on the inositol unit, respectively. In this case, the resultant GPI-protein conjugates can be used to investigate how the lipid chain may affect the structure and functions of GPI anchors and GPI-anchored proteins.

The synthesis of GPIs **1** and **2** is depicted in Scheme 2. Glycosylation of pseudodisaccharide **3** with trimannosyl donor **4**, prepared according to reported procedures,^{23,24} was α -selective to give a pseudopentasaccharide that was deacetylated under basic conditions to afford **5** in a 76% yield over two steps. The coupled DEPT NMR spectrum of **5** proved the α -configuration of all mannosyl residues judging from H1-C1 coupling constants. Phosphorylation of **5** was achieved by the one-pot two-step *H*-phosphonate method,²⁵ including reaction of **5** with **6** in the presence of pivaloyl chloride and thereafter oxidation of the resultant intermediate with iodine. Subsequently, **7** was treated with 5% trifluoroacetic acid in dichloromethane to get rid of the *para*-methoxybenzyl (PMB) protecting group, thereby to expose the inositol 1-*O*-position. Once again, the *H*-phosphonate method was used to install phosphoric acid and phospholipid moieties to **8** by means of **9** and **10**. Both reactions proceeded smoothly to give **11** and **12** in good yields. Finally, **11** and **12** were globally deprotected under a H₂ atmosphere in THF, MeOH, and H₂O (2:1:1) by using 10% Pd(OH)₂/C as the catalyst to generate the desired GPI anchors **1** and **2**, ready for SrtA-catalyzed coupling to proteins. All synthetic intermediates involved in the synthesis and the final products were characterized with NMR and mass spectroscopies.

In the meantime, small proteins **13** and **14** containing the sorting signal and the intact polypeptide sequences of the CD52²⁶ and CD24¹ antigens were prepared by solid-phase peptide synthesis. To achieve GPI-protein coupling, GPIs **1/2** and proteins **13/14** were incubated with SrtA at 37 °C in Tris-HCl buffer (0.3 M, pH 7.5) containing 150 mM NaCl, 5 mM CaCl₂, and 0.5 mM mercaptoethanol (Scheme 3). The peptide, GPI, and SrtA concentrations were 0.5 mM, 2.5 mM, and 30 μ M, respectively. Here, GPIs were used in relatively large excess (5 eq.), in order to suppress the reverse reaction. After 24 h of incubation, the reactions were quenched with 0.1% trifluoroacetic acid and then subjected to HPLC analysis and separation. It was observed that the reactions afforded the target molecules **15**, **16**, **17** and **18** in 45%, 48%, 69% and 51% yields, respectively. The reaction products were positively identified by MALDI-TOF MS. The calculated molecular weights of **15**, **16**, **17** and **18** were 2815, 4564 3067 and 4816, and their observed *m/z* values were 2814 (negative mode), 4563 (negative mode), 3068 (positive mode), and 4817 (positive mode), respectively. Furthermore, due to the presence of a lipid chain in the structure of **17** and **18**, these two conjugates ought to be more lipophilic than **15** and **16**. Indeed, it was found that while the HPLC retention time for **15** and **16** on a C-18 column eluted with 5%–20% aqueous CH₃CN was 20.9 and 24.0 min, respectively, **17** and **18** were retained by the C-18 column under the same conditions and could not be washed out even by a higher concentration of CH₃CN. The HPLC retention time for **17** and **18** on a C-8 column eluted

with 10%–80% aqueous CH₃CN was 31.9 and 31.2 min, respectively. These results provided additional proof to verify that in the presence of SrtA GPIs **1** and **2** were indeed coupled to proteins **13** and **14** to afford **15–18**.

In brief, several analogs of the human CD52 and CD24 antigens containing the common core of GPI anchors and the intact peptide sequences of CD52 and CD24 antigens were synthesized via SrtA-catalyzed ligation of synthetic GPI anchors and proteins. These CD52 and CD24 analogs are useful not only for the study of CD52 and CD24 but also for structural, functional, and various other biological studies of GPIs and GPI-anchored proteins. Furthermore, this work has proved that SrtA could accept intact GPIs as substrates for ligation with proteins, demonstrating that the SrtA-based synthetic strategy may be generally useful for other GPI-anchored proteins as well.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported in part by National Science Foundation (NSF CHE-1053848) of the USA (SrtA expression and enzymatic reactions), National Basic Research Program (973 Program) (2012CB822102) of China, and the National Institutes of Health (NIH, R01 GM090270) of the USA (GPI synthesis).

References

1. Kay RMRP, Humphries RK. *J Immunol.* 1991; 147:1412. [PubMed: 1831224]
2. Domagala A, Kurpisz M. *Med Sci Monit.* 2001; 7:325. [PubMed: 11257744]
3. Koyama K, Hasegawa A, Komori S. *J Reprod Immunol.* 2009; 83:56. [PubMed: 19875176]
4. Kirchhoff C. *Mol Hum Reprod.* 1996; 2:9. [PubMed: 9238651]
5. Poncet C, Frances V, Gristina R, Scheiner C, Pellissier JF, Figarella-Branger D. *Acta Neuropathol.* 1996; 91:400. [PubMed: 8928617]
6. Suzuki T, Kiyokawa N, Taguchi T, Sekino T, Katagiri YU, Fujimoto J. *J Immunol.* 2001; 166:5567. [PubMed: 11313396]
7. Kristiansen G, Sammar M, Altevogt P. *J Mol Histol.* 2004; 35:255. [PubMed: 15339045]
8. Lim SC. *Biomed Pharmacother.* 2005; 59(Suppl 2):S351. [PubMed: 16507407]
9. Zarn JA, Zimmermann SM, Pass MK, Waibel R, Stahel RA. *Biochem Biophys Res Commun.* 1996; 225:384. [PubMed: 8753773]
10. Ferguson MA, Williams AF. *Annu Rev Biochem.* 1988; 57:285. [PubMed: 3052274]
11. Englund PT. *Annu Rev Biochem.* 1993; 62:121. [PubMed: 8352586]
12. Hwa KY. *Adv Exp Med Biol.* 2001; 491:207. [PubMed: 14533800]
13. Gerold P, Eckert V, Schwarz RT. *Trends Glycosci Glycobiol.* 1996; 8:265.
14. Shao N, Xue J, Guo ZW. *Angew Chem Int Ed.* 2004; 43:1569.
15. Xue J, Shao N, Guo Z. *J Org Chem.* 2003; 68:4020. [PubMed: 12737586]
16. Paulick MG, Wise AR, Forstner MB, Groves JT, Bertozzi CR. *J Am Chem Soc.* 2007; 129:11543. [PubMed: 17715922]
17. Becker CFW, Liu XY, Olschewski D, Castelli R, Seidel R, Seeberger PH. *Angew Chem Int Ed.* 2008; 47:8215.
18. Guo X, Wang Q, Swarts BM, Guo Z. *J Am Chem Soc.* 2009; 131:9878. [PubMed: 19583255]
19. Wu Z, Guo X, Guo Z. *Chem Commun.* 2010; 46:5773.
20. Wu Z, Guo Z. *J Carbohydr Chem.* 2012; 31:48. [PubMed: 22468018]
21. Mazmanian SK, Liu G, Ton-That H, Schneewind O. *Science.* 1999; 285:760. [PubMed: 10427003]
22. Mazmanian SK, Ton-That H, Schneewind O. *Mol Microbiol.* 2001; 40:1049. [PubMed: 11401711]

23. Wu X, Guo Z. *Org Lett.* 2007; 9:4311. [PubMed: 17877362]
24. Pekari K, Tailler D, Weingart R, Schmidt RR. *J Org Chem.* 2001; 66:7432. [PubMed: 11681958]
25. Lindh I, Stawinski J. *J Org Chem.* 1989; 54:1338.
26. Treumann A, Lifely MR, Schneider P, Ferguson MAJ. *J Biol Chem.* 1995; 270:6088. [PubMed: 7890742]

Figure 1.
GPI anchors **1** and **2** used to synthesize CD52 and CD24 analogs

Scheme 1.

A general design for the synthesis of CD52 and CD24 analogs

Scheme 2.**Synthesis of GPI anchors 1 and 2**

Reaction conditions: (a) TMSOTf, Et₂O, -40 °C; (b) NaOMe, CH₂Cl₂/MeOH, 76% (over 2 steps); (c) PivCl, pyridine, rt; then I₂, pyridine/H₂O, 74%; (d) 5% TFA in CH₂Cl₂, 69%; (e) (1) PivCl, pyridine, rt; (2) I₂, pyridine/H₂O, 70%–72%; (f) H₂, 10% Pd(OH)₂/C, 76%–88%.

Scheme 3.

SrtA-mediated synthesis of CD52 and CD24 analogs